CBLL — CeriBell, Inc.

Ceribell (CBLL) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $22.6 million, a 31% increase from $17.2 million in Q3 2024.
• Product Revenue: $17 million, up 28% year-over-year.
• Subscription Revenue: $5.6 million, a 44% increase from $3.9 million in Q3 2024.
• Gross Margin: 88%, slightly up from 87% in the prior year.
• Net Loss: $13.5 million, or $0.37 per share, compared to a loss of $10.4 million, or $1.85 per share, in Q3 2024.
• Cash Position: $168.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025.

2. Strategic Updates and Business Highlights

• Account Growth: 615 active accounts, an increase of 31 accounts from the previous quarter, marking the largest sequential increase since going public.
• Market Opportunity: Ceribell aims to establish point-of-care EEG as a standard for seizure management, targeting a $2 billion market, with potential expansion into pediatric and neonatal markets adding approximately $400 million.
• Clinical Validation: The SAFER-EEG trial demonstrated significant reductions in time to EEG and improved patient outcomes, reinforcing the clinical value of the Ceribell system.
• VA System Expansion: Successful pilot programs have led to plans for broader adoption within the VA healthcare system.
• Product Development: Continued focus on expanding EEG capabilities into new conditions like delirium and stroke, with a commitment to making EEG a new vital sign in acute care.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year 2025 revenue is now expected to be between $87 million and $89 million, up from previous guidance of $85 million to $88 million, representing a year-over-year growth of 33% to 36%.
• Operational Strategy: The company plans to continue focusing on account penetration and utilization growth, particularly through protocol development and departmental expansion.

4. Challenges and Points of Concern

• Operating Expenses: Total operating expenses rose 39% year-over-year to $34.6 million, driven by investments in commercial infrastructure and legal expenses.
• Net Loss: The increase in net loss raises concerns about profitability timelines, especially as expenses outpace revenue growth.
• Competitive Pressures: Increased competition was noted, although Ceribell's performance remains strong. The company is actively monitoring competitive dynamics and adjusting strategies accordingly.
• Tariff Impacts: Transitioning to manufacturing in Vietnam is expected to mitigate tariff impacts, but the transition period may affect margins in the short term.

5. Notable Q&A Insights

• 2026 Outlook: Management refrained from providing specific guidance for 2026 but emphasized that growth drivers remain consistent.
• Neonatal Market Launch: Plans for launching neonatal products will involve both expanding existing accounts and acquiring new ones, with a focus on Level 3 and Level 4 NICUs.
• Utilization Trends: Increased utilization is being driven across various departments, with notable growth in emergency departments due to lower penetration rates.
• IDN Engagement: Ceribell is focusing on engaging Integrated Delivery Networks (IDNs) more systematically to leverage best practices across hospital systems.
• 510(k) Clearance: Recent clearance for the neonatal headcap is expected to enhance product offerings and market acceptance.

Overall, Ceribell reported strong growth in Q3 2025, driven by increased account adoption and utilization, while also navigating challenges related to operating expenses and competitive pressures. The company remains optimistic about future growth opportunities, particularly in expanding its market presence and product offerings.